Takeda Gets New India Chief, Mandate To Broaden Access
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
You may also be interested in...
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.
Eisai Pharmaceuticals India's managing director has left the company and plans to start his own venture.
Takeda has introduced rare disease therapies from Shire’s portfolio in India and appears to be shifting gears in a market where it has long adopted a measured approach. But pricing and access to these products pose challenges that the Japanese multinational will need to address.